These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 24891360)
1. Second-generation ALK inhibitors: filling the non "MET" gap. Ramalingam SS; Khuri FR Cancer Discov; 2014 Jun; 4(6):634-6. PubMed ID: 24891360 [TBL] [Abstract][Full Text] [Related]
2. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041 [TBL] [Abstract][Full Text] [Related]
3. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. Croegaert K; Kolesar JM Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238 [TBL] [Abstract][Full Text] [Related]
4. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186 [TBL] [Abstract][Full Text] [Related]
5. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534 [TBL] [Abstract][Full Text] [Related]
7. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
8. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591 [TBL] [Abstract][Full Text] [Related]
9. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422 [TBL] [Abstract][Full Text] [Related]
11. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. Zhu Q; Hu H; Weng DS; Zhang XF; Chen CL; Zhou ZQ; Tang Y; Xia JC BMC Cancer; 2017 Jun; 17(1):412. PubMed ID: 28606126 [TBL] [Abstract][Full Text] [Related]
12. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571 [TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079 [TBL] [Abstract][Full Text] [Related]
14. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Toyokawa G; Seto T; Takenoyama M; Ichinose Y Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831 [TBL] [Abstract][Full Text] [Related]
15. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177 [TBL] [Abstract][Full Text] [Related]
16. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430 [TBL] [Abstract][Full Text] [Related]
17. Advances in the battle against lung tumour resistance. Furlow B Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524 [No Abstract] [Full Text] [Related]
18. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553 [TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979 [TBL] [Abstract][Full Text] [Related]
20. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]